FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992953921> ?p ?o ?g. }

• W1992953921 endingPage "6037" @default.
• W1992953921 startingPage "6033" @default.
• W1992953921 abstract "During the past 2 decades, the elucidation of susceptibility and causative genes for Alzheimer disease as well as proteins involved in the pathogenic process has greatly facilitated the development of genetically altered mouse models. These models have played a major role in defining critical disease-related mechanisms and in evaluating novel therapeutic approaches, with many treatments currently in clinical trial owing their origins to studies initially performed in mice. This review discusses the utility of transgenic mice as a research tool and their contributions to our understanding of Alzheimer disease. During the past 2 decades, the elucidation of susceptibility and causative genes for Alzheimer disease as well as proteins involved in the pathogenic process has greatly facilitated the development of genetically altered mouse models. These models have played a major role in defining critical disease-related mechanisms and in evaluating novel therapeutic approaches, with many treatments currently in clinical trial owing their origins to studies initially performed in mice. This review discusses the utility of transgenic mice as a research tool and their contributions to our understanding of Alzheimer disease. The most common cause of dementia, AD 2The abbreviations used are: AD, Alzheimer disease; SAD, sporadic AD; FAD, familial AD; APP, amyloid precursor protein; PS, presenilin; Aβ, amyloid β-protein; NFT, neurofibrillary tangle; Tg, transgenic; LTP, long-term potentiation. accounts for 60–70% of all dementia cases and afflicts >15 million individuals worldwide. The disorder is characterized by severe memory loss, with episodic memory being particularly impaired during the initial phases. At present, the disorder is not curable. Most AD cases occur sporadically (SAD), although inheritance of certain susceptibility genes enhances the risk. A small minority of AD cases (<1%) is inheritable (referred to as FAD) and is caused by mutations in genes encoding APP, PS1, or PS2. Definitive diagnosis of AD occurs during post-mortem examination upon detection of two hallmark pathologies. The first is amyloid plaques, which consist of Aβ. The length of Aβ can vary, but a 42-amino acid variant is considered neurotoxic because of its propensity to readily aggregate into oligomers and fibrils. All mutations associated with FAD affect the aggregation and/or production of Aβ, which is sequentially cleaved from the APP holoprotein, first by an enzyme known as BACE (beta-APP-cleaving enzyme) and then by an enzymatic complex known as γ-secretase, in which the presenilins form the catalytic core (1Wolfe M.S. Biochemistry. 2006; 45: 7931-7939Crossref PubMed Scopus (180) Google Scholar). FAD-associated mutations in APP cluster around the β-secretase cleavage site (e.g. Swedish mutation), in key amino acids affecting its ability to aggregate (e.g. Arctic and Dutch mutations), or around the γ-secretase cleavage site, which increases production of the longer Aβ42 peptide (e.g. London mutation). PS mutations play a similar role by favoring production of Aβ42 at the expense of Aβ40. In vitro experiments and transgenic mice have shown us that the aggregation state of Aβ is crucial, that it can also accumulate intraneuronally, and that it can mediate a diverse range of pathological effects on cellular function (2LaFerla F.M. Green K.N. Oddo S. Nat. Rev. Neurosci. 2007; 8: 499-509Crossref PubMed Scopus (1572) Google Scholar). The second pathological hallmark is the appearance of intraneuronal aggregates composed of the microtubule-associated protein tau. Hyperphosphorylation of tau leads it to dissociate from the microtubules and aggregate within the axoplasm as NFTs (3Iqbal K. Alonso Adel C. Chen S. Chohan M.O. El-Akkad E. Gong C.X. Khatoon S. Li B. Liu F. Rahman A. Tanimukai H. Grundke-Iqbal I. Biochim, Biophys. Acta. 2005; 1739: 198-210Crossref PubMed Scopus (741) Google Scholar). Furthermore, tau dissociation leads to a reduction in microtubule stability and impaired axonal transport, ultimately leading to neuronal dysfunction and loss of synapses and subsequent retrograde degeneration (4Iqbal K. Grundke-Iqbal I. Acta Neuropathol. 2005; 109: 25-31Crossref PubMed Scopus (89) Google Scholar). Mutations in the gene for tau (MAPT) are not associated with AD but cause FTDP-17 (frontal temporal dementia with parkinsonism 17), showing that disruption of tau function directly leads to neurodegeneration. Besides these two hallmark lesions, other reactive processes occur such as inflammation (5Eikelenboom P. Veerhuis R. Scheper W. Rozemuller A.J. van Gool W.A. Hoozemans J.J. J. Neural Transm. 2006; 113: 1685-1695Crossref PubMed Scopus (239) Google Scholar) and additional disturbances in cellular function through calcium dyshomeostasis (6Green K.N. LaFerla F.M. Neuron. 2008; 59: 190-194Abstract Full Text Full Text PDF PubMed Scopus (277) Google Scholar) and oxidative stress (7Akiyama H. Barger S. Barnum S. Bradt B. Bauer J. Cole G.M. Cooper N.R. Eikelenboom P. Emmerling M. Fiebich B.L. Finch C.E. Frautschy S. Griffin W.S. Hampel H. Hull M. Landreth G. Lue L. Mrak R. Mackenzie I.R. McGeer P.L. O’Banion M.K. Pachter J. Pasinetti G. Plata-Salaman C. Rogers J. Rydel R. Shen Y. Streit W. Strohmeyer R. Tooyoma I. Van Muiswinkel F.L. Veerhuis R. Walker D. Webster S. Wegrzyniak B. Wenk G. Wyss-Coray T. Neurobiol. Aging. 2000; 21: 383-421Crossref PubMed Scopus (3705) Google Scholar), which cumulatively cause marked cortical and hippocampal neuronal and synaptic loss. The amyloid cascade hypothesis, first proposed by Hardy and Higgins in 1992 (8Hardy J.A. Higgins G.A. Science. 1992; 256: 184-185Crossref PubMed Scopus (5119) Google Scholar) and refined over the years, postulates that Aβ triggers the development of AD and that the other phenotypic alterations, including tau pathology and behavioral deficits, are a downstream consequence. This hypothesis has been supported by a wealth of evidence (9Hardy J. Curr. Alzheimer Res. 2006; 3: 71-73Crossref PubMed Scopus (209) Google Scholar), not the least of which is the fact that all AD-related mutations result in increased Aβ accumulation. The hypothesis assumes that FAD and SAD manifest as the same disease but with different underlying causes, genetic in the case of the former and unknown in the case of the latter, although both exhibit an aging component. Transgenic mice that overproduce Aβ mimic many facets of the human disease and lend credence to the amyloid cascade hypothesis. These mice have allowed us to understand more about the course of the disease and how the pathology affects the local brain environment to cause cognitive deterioration and to explore potential therapeutic avenues. Although these mice do not mimic several aspects of the human disorder, these differences have led to some of the more intriguing discussions about human AD. APP-overproducing mice develop amyloid deposits similar to those found in the human brain in an age-dependent fashion (supplemental Table 1). Despite chronic APP production, plaques typically accumulate in mid-to-late adulthood in the majority of these animals, although this is largely dependent on expression levels or the number of FAD mutations introduced. Notably, plaque formation is accelerated when the longer Aβ42 is preferentially cleaved from APP, as this peptide is more prone to aggregate than Aβ40 and leads to earlier and more severe cognitive decline (10Findeis M.A. Pharmacol. Ther. 2007; 116: 266-286Crossref PubMed Scopus (250) Google Scholar). The importance of Aβ42 to disease progression was highlighted by showing that elevated levels of Aβ40, the shorter more common form of Aβ, actually prevented the formation of Aβ pathology in the widely used Tg2576 mouse model. On the contrary, elevated levels of Aβ42 markedly exacerbated pathology in the same mouse model (11McGowan E. Pickford F. Kim J. Onstead L. Eriksen J. Yu C. Skipper L. Murphy M.P. Beard J. Das P. Jansen K. Delucia M. Lin W.L. Dolios G. Wang R. Eckman C.B. Dickson D.W. Hutton M. Hardy J. Golde T. Neuron. 2005; 47: 191-199Abstract Full Text Full Text PDF PubMed Scopus (469) Google Scholar). Aβ plaques found in the brains of AD Tg mice appear structurally similar to those found in the human brain; they initiate as diffuse plaques consisting mainly of Aβ42, develop a dense Aβ42 core, and then incorporate Aβ40 as well as numerous other non-Aβ components such as ubiquitin and α-synuclein (12Yang F. Ueda K. Chen P. Ashe K.H. Cole G.M. Brain Res.. 2000; 853: 381-383Crossref PubMed Scopus (54) Google Scholar). Positron emission tomography (PET) imaging indicates that the radiotracer Pittsburgh Compound B binds to Aβ deposits in mice with less affinity than to human Aβ deposits, possibly due to the increased levels of pyroglutamate in human Aβ deposits (13Maeda J. Ji B. Irie T. Tomiyama T. Maruyama M. Okauchi T. Staufenbiel M. Iwata N. Ono M. Saido T.C. Suzuki K. Mori H. Higuchi M. Suhara T. J. Neurosci. 2007; 27: 10957-10968Crossref PubMed Scopus (259) Google Scholar). However, work in Tg mice has highlighted the dynamic nature of extracellular plaques and has also aided in the clarification of important elements in both the brain environment and the Aβ peptide needed for aggregation of Aβ into plaques. Although formation of plaques in AD Tg mice is typically age-dependent (as is AD pathology in humans), plaque formation occurs very quickly in the brains of older AD Tg mice. This has been shown by creating a “window” in the skulls of APP Tg mice (14Meyer-Luehmann M. Spires-Jones T.L. Prada C. Garcia-Alloza M. de Calignon A. Rozkalne A. Koenigsknecht-Talboo J. Holtzman D.M. Bacskai B.J. Hyman B.T. Nature. 2008; 451: 720-724Crossref PubMed Scopus (816) Google Scholar) and further supported by data showing that plaque volume in aged AD Tg mice rapidly returns to high levels within 30 days following plaque removal by immunotherapy (15Oddo S. Billings L. Kesslak J.P. Cribbs D.H. LaFerla F.M. Neuron. 2004; 43: 321-332Abstract Full Text Full Text PDF PubMed Scopus (734) Google Scholar), in grafts of wild-type tissue into AD Tg mouse brains (16Meyer-Luehmann M. Stalder M. Herzig M.C. Kaeser S.A. Kohler E. Pfeifer M. Boncristiano S. Mathews P.M. Mercken M. Abramowski D. Staufenbiel M. Jucker M. Nat. Neurosci. 2003; 6: 370-377Crossref PubMed Scopus (103) Google Scholar), and in the brains of pre-pathological AD Tg mice following injection with extracts from human AD brain or aged AD Tg mouse brain (17Roberson E.D. Scearce-Levie K. Palop J.J. Yan F. Cheng I.H. Wu T. Gerstein H. Yu G.Q. Mucke L. Science. 2007; 316: 750-754Crossref PubMed Scopus (1493) Google Scholar). These data indicate that the adult AD Tg mouse brain is ripe for the development of Aβ pathology, and the latter study also suggests that the ability of Aβ to act as a seed for aggregation is dependent on its source. Although some differences have been shown between Aβ pathology in human AD and mice overexpressing human APP (18Kuo Y.M. Kokjohn T.A. Beach T.G. Sue L.I. Brune D. Lopez J.C. Kalback W.M. Abramowski D. Sturchler-Pierrat C. Staufenbiel M. Roher A.E. J. Biol. Chem. 2001; 276: 12991-12998Abstract Full Text Full Text PDF PubMed Scopus (234) Google Scholar), AD Tg mice develop Aβ plaques that are remarkably similar to those seen in humans. The majority of AD Tg models exhibit memory impairments on various cognitive tests (19Kobayashi D.T. Chen K.S. Genes Brain Behav. 2005; 4: 173-196Crossref PubMed Scopus (155) Google Scholar). Critically, cognitive deficits in AD Tg mice occur prior to the appearance of extracellular plaques (20Eriksen J.L. Janus C.G. Behav. Genet. 2007; 37: 79-100Crossref PubMed Scopus (120) Google Scholar). These observations precipitated a search for the soluble pathological Aβ culprit mediating cognitive decline, with emphasis shifting toward identifying the precursors to plaques. This led to the focus on soluble oligomeric Aβ species, aggregates up to ∼150 kDa consisting of 2–30 Aβ peptides. As in AD Tg mice, cognitive decline in humans is not proportional to Aβ plaque load (21Terry R.D. Masliah E. Salmon D.P. Butters N. DeTeresa R. Hill R. Hansen L.A. Katzman R. Ann. Neurol. 1991; 30: 572-580Crossref PubMed Scopus (3399) Google Scholar) but does correlate with soluble Aβ species (22Wang J. Dickson D.W. Trojanowski J.Q. Lee V.M. Exp. Neurol. 1999; 158: 328-337Crossref PubMed Scopus (460) Google Scholar). The latest data now indicate that soluble oligomeric species play a critical role in the pathogenicity of AD (23Walsh D.M. Selkoe D.J. J. Neurochem. 2007; 101: 1172-1184Crossref PubMed Scopus (1669) Google Scholar). Evidence supporting involvement of soluble Aβ oligomers in AD has come from human post-mortem brain tissue (24Kokubo H. Kayed R. Glabe C.G. Yamaguchi H. Brain Res. 2005; 1031: 222-228Crossref PubMed Scopus (107) Google Scholar, 25Shankar G.M. Li S. Mehta T.H. Garcia-Munoz A. Shepardson N.E. Smith I. Brett F.M. Farrell M.A. Rowan M.J. Lemere C.A. Regan C.M. Walsh D.M. Sabatini B.L. Selkoe D.J. Nat. Med. 2008; 14: 837-842Crossref PubMed Scopus (2916) Google Scholar); however, much of the evidence for the toxicity of oligomeric Aβ and its central part in AD has come directly from the use of Tg mouse models of AD. Using the Tg2576 mouse, Ashe and co-workers (26Lesne S. Koh M.T. Kotilinek L. Kayed R. Glabe C.G. Yang A. Gallagher M. Ashe K.H. Nature. 2006; 440: 352-357Crossref PubMed Scopus (2430) Google Scholar) recently identified a memory-impairing oligomeric Aβ species as a 56-kDa soluble protein assembly termed Aβ*56, which others have also confirmed (27Oddo S. Vasilevko V. Caccamo A. Kitazawa M. Cribbs D.H. LaFerla F.M. J. Biol. Chem. 2006; 281: 39413-39423Abstract Full Text Full Text PDF PubMed Scopus (265) Google Scholar). Intraneuronal Aβ has also gained experimental support in recent years (2LaFerla F.M. Green K.N. Oddo S. Nat. Rev. Neurosci. 2007; 8: 499-509Crossref PubMed Scopus (1572) Google Scholar). The accumulation of intracellular Aβ has been shown to precede extracellular deposition in both humans (28Mori C. Spooner E.T. Wisniewsk K.E. Wisniewski T.M. Yamaguch H. Saido T.C. Tolan D.R. Selkoe D.J. Lemere C.A. Amyloid. 2002; 9: 88-102Crossref PubMed Scopus (218) Google Scholar) and mice (29Oddo S. Caccamo A. Shepherd J.D. Murphy M.P. Golde T.E. Kayed R. Metherate R. Mattson M.P. Akbari Y. LaFerla F.M. Neuron. 2003; 39: 409-421Abstract Full Text Full Text PDF PubMed Scopus (3195) Google Scholar). In fact, it was found in Tg mice that intraneuronal Aβ strongly correlates with initial deficits in a hippocampus-based memory task (30Billings L.M. Oddo S. Green K.N. McGaugh J.L. LaFerla F.M. Neuron. 2005; 45: 675-688Abstract Full Text Full Text PDF PubMed Scopus (1048) Google Scholar), a result that supports a pathological basis of intraneuronal Aβ in mild cognitive impairment, which is often a harbinger for AD. Data from AD Tg mice also indicate that intraneuronal Aβ is more neurotoxic than extracellular Aβ (31Casas C. Sergeant N. Itier J.M. Blanchard V. Wirths O. van der Kolk N. Vingtdeux V. van de Steeg E. Ret G. Canton T. Drobecq H. Clark A. Bonici B. Delacourte A. Benavides J. Schmitz C. Tremp G. Bayer T.A. Benoit P. Pradier L. Am. J. Pathol. 2004; 165: 1289-1300Abstract Full Text Full Text PDF PubMed Scopus (352) Google Scholar). Tau pathology is the other hallmark of AD. The Aβ cascade hypothesis predicts that tau hyperphosphorylation occurs as a downstream consequence of Aβ accumulation. APP-overexpressing Tg mice have provided evidence both for and against this. APP-overexpressing models do not develop NFTs, yet many do show detectable tau hyperphosphorylation (32Gotz J. Deters N. Doldissen A. Bokhari L. Ke Y. Wiesner A. Schonrock N. Ittner L.M. Brain Pathol. 2007; 17: 91-103Crossref PubMed Scopus (153) Google Scholar). This could be because human Aβ accumulation does not induce NFT formation, although it is more likely that rodent tau has a different structure and sequence, rendering it more resistant to aggregate formation, and/or the life span of mice is not long enough to allow for hyperphosphorylation/aggregation, which implies that Aβ alone cannot induce tau pathology but requires an age-dependent cofactor or “second hit.” So although Aβ accumulation in APP-overexpressing mice does not lead to NFT formation, it should be remembered that these animals still develop robust cognitive decline and also undergo more subtle alterations in tau that resemble the precursors to NFTs in the human brain (most notably hyperphosphorylated tau). In fact, recent evidence has highlighted tau as being critical in mediating the cognitive decline brought about by accumulation of Aβ. It was shown that knocking out endogenous MAPT in APP-overexpressing mice prevented cognitive decline despite abundant Aβ accumulation (17Roberson E.D. Scearce-Levie K. Palop J.J. Yan F. Cheng I.H. Wu T. Gerstein H. Yu G.Q. Mucke L. Science. 2007; 316: 750-754Crossref PubMed Scopus (1493) Google Scholar). These data and others highlight a parallel to the Aβ peptide; it is the soluble species that mediates toxicity rather than the aggregated species. More so, it has been observed that Aβ oligomers can lead to tau pathology through activation of tau kinases such as GSK-3β (glycogen synthase kinase 3β) and through inhibition of the proteasome (33Blurton-Jones M. Laferla F.M. Curr. Alzheimer Res. 2006; 3: 437-448Crossref PubMed Scopus (169) Google Scholar). To model NFTs, it has been necessary to develop Tg mice that express further gene alterations in addition to mutant APP such as mutant human MAPT (29Oddo S. Caccamo A. Shepherd J.D. Murphy M.P. Golde T.E. Kayed R. Metherate R. Mattson M.P. Akbari Y. LaFerla F.M. Neuron. 2003; 39: 409-421Abstract Full Text Full Text PDF PubMed Scopus (3195) Google Scholar, 34Lewis J. Dickson D.W. Lin W.L. Chisholm L. Corral A. Jones G. Yen S.H. Sahara N. Skipper L. Yager D. Eckman C. Hardy J. Hutton M. McGowan E. Science. 2001; 293: 1487-1491Crossref PubMed Scopus (1278) Google Scholar) or removal of nitricoxide synthase 2 (35Wilcock D.M. Lewis M.R. Van Nostrand W.E. Davis J. Previti M.L. Gharkholonarehe N. Vitek M.P. Colton C.A. J. Neurosci. 2008; 28: 1537-1545Crossref PubMed Scopus (140) Google Scholar). These multigenic AD Tg models do develop NFTs similar to those seen in human brain and have aided the explication of the relationship between Aβ and tau (33Blurton-Jones M. Laferla F.M. Curr. Alzheimer Res. 2006; 3: 437-448Crossref PubMed Scopus (169) Google Scholar), with Aβ pathology seeming to precede the onset of tau pathology. In addition to providing evidence that Aβ accumulation occurs proximal to the onset of tau pathology, multigenic models of AD have also allowed us to determine how manipulation of Aβ affects tau and vice versa. Some of the strongest data supporting tau pathology as a downstream event of Aβ accumulation have come from the study of Tg mice. For example, in 3× Tg-AD mice, which contain human APP, PS1, and MAPT mutant transgenes, the appearance of intraneuronal Aβ precedes somatodendritic accumulation of tau (36Oddo S. Caccamo A. Kitazawa M. Tseng B.P. LaFerla F.M. Neurobiol. Aging. 2003; 24: 1063-1070Crossref PubMed Scopus (757) Google Scholar). Furthermore, removal of intraneuronal Aβ via immunotherapy leads to the removal of somatodendritic tau shortly afterward, provided tau is not aggregated (15Oddo S. Billings L. Kesslak J.P. Cribbs D.H. LaFerla F.M. Neuron. 2004; 43: 321-332Abstract Full Text Full Text PDF PubMed Scopus (734) Google Scholar). It was also found that Aβ oligomers inhibit proteasome function, which normally serves to degrade excess tau proteins, leading to tau accumulation (37Oddo S. J. Cell. Mol. Med. 2008; 12: 363-373Crossref PubMed Scopus (191) Google Scholar). Such impairments in proteasome activity have been shown in human AD as well (38Keller J.N. Hanni K.B. Markesbery W.R. J. Neurochem. 2000; 75: 436-439Crossref PubMed Scopus (694) Google Scholar). Notably, reduction of tau pathology in these mice is necessary to ameliorate behavioral deficits (17Roberson E.D. Scearce-Levie K. Palop J.J. Yan F. Cheng I.H. Wu T. Gerstein H. Yu G.Q. Mucke L. Science. 2007; 316: 750-754Crossref PubMed Scopus (1493) Google Scholar, 27Oddo S. Vasilevko V. Caccamo A. Kitazawa M. Cribbs D.H. LaFerla F.M. J. Biol. Chem. 2006; 281: 39413-39423Abstract Full Text Full Text PDF PubMed Scopus (265) Google Scholar) and further supports the notion that Aβ accumulation impacts cognition via tau protein. A further connection between Aβ aggregation and downstream pathologies, such as tau, exists in the inflammatory response present in AD. Inflammation in AD is not exactly modeled in mice, as there are differences between humans and AD Tg mice with respect to the nature and severity of the inflammation (39Webster S.D. Tenner A.J. Poulos T.L. Cribbs D.H. Neurobiol. Aging. 1999; 20: 297-304Crossref PubMed Scopus (38) Google Scholar), yet AD Tg mice are still valuable for revealing which aspects of inflammation may be key for the development or elimination of downstream pathologies. Data from AD Tg mice indicate that inflammation, including activation of complement and various cytokines, occurs downstream from the aggregation of Aβ (7Akiyama H. Barger S. Barnum S. Bradt B. Bauer J. Cole G.M. Cooper N.R. Eikelenboom P. Emmerling M. Fiebich B.L. Finch C.E. Frautschy S. Griffin W.S. Hampel H. Hull M. Landreth G. Lue L. Mrak R. Mackenzie I.R. McGeer P.L. O’Banion M.K. Pachter J. Pasinetti G. Plata-Salaman C. Rogers J. Rydel R. Shen Y. Streit W. Strohmeyer R. Tooyoma I. Van Muiswinkel F.L. Veerhuis R. Walker D. Webster S. Wegrzyniak B. Wenk G. Wyss-Coray T. Neurobiol. Aging. 2000; 21: 383-421Crossref PubMed Scopus (3705) Google Scholar) and, more specifically, in association with fibrillar Aβ (40Kitazawa M. Oddo S. Yamasaki T.R. Green K.N. LaFerla F.M. J. Neurosci. 2005; 25: 8843-8853Crossref PubMed Scopus (539) Google Scholar). Many of these inflammatory mediators that are up-regulated by Aβ can serve to increase tau pathology (33Blurton-Jones M. Laferla F.M. Curr. Alzheimer Res. 2006; 3: 437-448Crossref PubMed Scopus (169) Google Scholar). Reactive oxygen species are also produced as a result of this inflammatory response (41Steele M. Stuchbury G. Munch G. Exp. Gerontol. 2007; 42: 28-36Crossref PubMed Scopus (100) Google Scholar), which is damaging to cell membranes and may further exacerbate the inflammatory response. In both humans and AD Tg mice, Aβ plaques are surrounded by activated microglia and astrocytes; thus, even as the activation of the inflammatory response in AD can lead to the detrimental effects discussed above, activated microglia act in a beneficial manner by attempting to phagocytose Aβ plaques (42Wyss-Coray T. Mucke L. Neuron. 2002; 35: 419-432Abstract Full Text Full Text PDF PubMed Scopus (991) Google Scholar). In support of the hypothesis that inflammation may have favorable effects in AD, acute inflammation, as brought about by treatment with lipopolysaccharide, has been shown to clear Aβ plaques (43DiCarlo G. Wilcock D. Henderson D. Gordon M. Morgan D. Neurobiol. Aging. 2001; 22: 1007-1012Crossref PubMed Scopus (195) Google Scholar) in AD Tg mice, whereas more chronic lipopolysaccharide treatment potentiates tau pathology (40Kitazawa M. Oddo S. Yamasaki T.R. Green K.N. LaFerla F.M. J. Neurosci. 2005; 25: 8843-8853Crossref PubMed Scopus (539) Google Scholar). Aβ immunotherapy strategies have also proven useful in reducing plaque and, subsequently, tangle pathology as well as cognitive deficits in AD Tg mice (15Oddo S. Billings L. Kesslak J.P. Cribbs D.H. LaFerla F.M. Neuron. 2004; 43: 321-332Abstract Full Text Full Text PDF PubMed Scopus (734) Google Scholar, 44Morgan D. J. Alzheimer’s Dis. 2006; 9: 425-432Crossref PubMed Google Scholar). AD Tg mice have not only allowed us to study the relationship of obvious AD pathologies such as amyloid accumulation and inflammation to one another, they have also allowed us to study aspects of AD that are inaccessible in humans and the effects of amyloid accumulation on such features. Whereas loss of synapses strongly correlates with cognitive deficits in humans (45DeKosky S.T. Scheff S.W. Ann. Neurol. 1990; 27: 457-464Crossref PubMed Scopus (1680) Google Scholar), the relationship between synaptic deficits and progression of AD is more difficult to ascertain. For instance, LTP is a mechanism of synaptic plasticity implicated in learning and memory; however, LTP deficits in humans with AD can only be speculated upon. AD Tg mice have allowed us to determine that Aβ accumulation (and more specifically, intraneuronal Aβ) leads to impaired LTP in an age-dependent manner (46Green K.N. Smith I.F. Laferla F.M. Subcell. Biochem. 2007; 45: 507-521Crossref PubMed Scopus (51) Google Scholar), supporting the notion that synaptic dysfunction may contribute to the cognitive deficits seen in AD. Recent evidence indicates that N-methyl-d-aspartate and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, both instrumental to the development of LTP, are reduced in AD Tg brain in part due to their endocytosis following exposure to Aβ (47Snyder E.M. Nong Y. Almeida C.G. Paul S. Moran T. Choi E.Y. Nairn A.C. Salter M.W. Lombroso P.J. Gouras G.K. Greengard P. Nat. Neurosci. 2005; 8: 1051-1058Crossref PubMed Scopus (1302) Google Scholar). The synaptic dysfunction in AD Tg mice precedes Aβ deposition (48Xie C.W. NeuroMol. Med. 2004; 6: 53-64Crossref PubMed Google Scholar), and in agreement with the damaging effects of oligomeric Aβ species on cognitive functioning discussed above, the synaptic dysfunction is especially correlated with soluble oligomeric Aβ species, with relevant data coming from AD Tg mice as well as studies involving the injection of oligomeric Aβ into rat brain (49Selkoe D.J. Science. 2002; 298: 789-791Crossref PubMed Scopus (3408) Google Scholar). Remarkably, there is evidence for a negative feedback loop between Aβ production and synaptic transmission whereby increased neuronal activity leads to amplified β-secretase cleavage (and subsequent production of Aβ), whereas Aβ depresses synaptic transmission (50Kamenetz F. Tomita T. Hsieh H. Seabrook G. Borchelt D. Iwatsubo T. Sisodia S. Malinow R. Neuron. 2003; 37: 925-937Abstract Full Text Full Text PDF PubMed Scopus (1285) Google Scholar). One can speculate that this feedback loop is severely disrupted in the AD brain, leading to both synaptic dysfunction and unchecked Aβ production. AD Tg mice have thus been instrumental in allowing researchers to explore the physiological function as well as the pathological consequences of Aβ on synaptic function, which may be key to the memory impairments seen in the earlier stages of AD. The effects of Aβ on synapse structure and function are of key interest given that one aspect of human AD not recapitulated in most AD Tg mice is abundant neuronal loss. The lack of cell loss in most AD Tg models has provided evidence that cognitive decline in AD may not be due solely to the loss of neurons. Although there is no significant cell loss in most AD Tg mouse models, virtually all AD Tg mice show cognitive deficits. In addition to the synaptic dysfunction discussed above, the memory deficits in AD, at least in the earlier stages, may be due to structural neuronal damage (such as loss of dendritic spines or synapses), which is seen in both humans (21Terry R.D. Masliah E. Salmon D.P. Butters N. DeTeresa R. Hill R. Hansen L.A. Katzman R. Ann. Neurol. 1991; 30: 572-580Crossref PubMed Scopus (3399) Google Scholar) and AD Tg mice (51Bell K.F. Claudio Cuello A. Eur. J. Pharmacol. 2006; 545: 11-21Crossref PubMed Scopus (90) Google Scholar) or dysfunction at the level of the synapse. In fact, a recent study has given evidence that Aβ oligomers can induce loss of proteins involved in spine structuring and that this loss is well correlated with cognitive deficits (52Zhao L. Ma Q.L. Calon F. Harris-White M.E. Yang F. Lim G.P. Morihara T. Ubeda O.J. Ambegaokar S. Hansen J.E. Weisbart R.H. Teter B. Frautschy S.A. Cole G.M. Nat. Neurosci. 2006; 9: 234-242Crossref PubMed Scopus (267) Google Scholar). Tau pathology may also be important for the development of cognitive deficits because reduction in soluble tau (27Oddo S. Vasilevko V. Caccamo A. Kitazawa M. Cribbs D.H. LaFerla F.M. J. Biol. Chem. 2006; 281: 39413-39423Abstract Full Text Full Text PDF PubMed Scopus (265) Google Scholar) or in endogenous MAPT expression (17Roberson E.D. Scearce-Levie K. Palop J.J. Yan F. Cheng I.H. Wu T. Gerstein H. Yu G.Q. Mucke L. Science. 2007; 316: 750-754Crossref PubMed Scopus (1493) Google Scholar) is beneficial to the amelioration of cognitive impairments in AD Tg mice. Reduction in endogenous mouse tau has also been shown to decrease susceptibility to excitotoxicity (17Roberson E.D. Scearce-Levie K. Palop J.J. Yan F. Cheng I.H. Wu T. Gerstein H. Yu G.Q. Mucke L. Science. 2007; 316: 750-754Crossref PubMed Scopus (1493) Google Scholar). As Aβ has been shown to increase glutamatergic excitotoxicity (53Koh J.Y. Yang L.L. Cotman C.W. Brain Res. 1990; 533: 315-320Crossref PubMed Scopus (610) Google Scholar), it may be that cognitive deficits in AD are due to excitotoxicity (as permitted by tau) in addition to (or in conjunction with) neuronal and/or synaptic loss and synaptic dysfunction. The fact that Aβ pathology occurs separately from both NFTs and neuronal cell loss in AD Tg mice has allowed researchers to investigate the distinct contributions made by each of these pathologies. The involvement of Aβ-induced glutamatergic alterations and excitotoxicity compounds one specific concern with regard to Tg mouse models that has gained increasing attention in recent years: mouse genetic background strain. There are several characteristics that differ depending on mouse genetic background strain, and many of these may be highly relevant to the etiology, development, and consequence of Aβ pathology. Of specific relevance to AD research, mouse strain variation has been observed with respect to susceptibility to excitotoxins (54Schauwecker P.E. Exp. Neurol. 2002; 178: 219-235Crossref PubMed Scopus (67) Google Scholar, 55Shuttleworth C.W. Connor J.A. J. Neurosci. 2001; 21: 4225-4236Crossref PubMed Google Scholar) in that some strains are vulnerable to excitotoxic insult, whereas others (including the most commonly used AD Tg mouse background strain, C57/BL6) are not. Therefore, one reason underlying the lack of neuronal cell loss comparable with that seen in human brains in most AD Tg mice may be the inherent cellular resistance of current AD Tg models to excitotoxic damage from Aβ and downstream effectors. In addition, one research team has determined that background strain significantly modulates processing of APP as well as deposition of Aβ into plaques (56Lehman E.J. Kulnane L.S. Gao Y. Petriello M.C. Pimpis K.M. Younkin L. Dolios G. Wang R. Younkin S.G. Lamb B.T. Hum. Mol. Genet. 2003; 12: 2949-2956Crossref PubMed Scopus (77) Google Scholar). These data indicate that generation of AD Tg mouse models should involve expression of human genes in mouse genetic background strains that allow for the most “human-like” Aβ aggregation and the most complete spectrum of downstream cascades from Aβ accumulation. It is not yet completely understood which mouse strain variations best mimic what is found in humans susceptible to AD, but it is interesting to speculate how some of the variability between mouse strains may be comparable with human populations such as those who develop SAD versus those who do not. The etiology of the vast majority of AD cases still remains unknown. Existing models of AD solely mimic the rare familial forms of AD. One future goal will be to develop models of SAD. Future model development will seek to recapitulate AD-like pathologies by utilizing natural genetic modifications rather than introducing additional mutated human genes. This may be accomplished by utilizing mouse strains with inherent characteristics (such as susceptibility to excitotoxicity) that would exacerbate pathological and behavioral consequences of Aβ accumulation. Studies with AD Tg mice have informed us that many different factors affect the course of AD, and as such, combination therapies targeting both AD pathogenic proteins (Aβ and tau), immunologic modulation, oxidative stress, and lifestyle modifications may bring about the most effective treatment course. In fact, such combination strategies for treatment are gaining support from emerging studies in AD Tg mice (27Oddo S. Vasilevko V. Caccamo A. Kitazawa M. Cribbs D.H. LaFerla F.M. J. Biol. Chem. 2006; 281: 39413-39423Abstract Full Text Full Text PDF PubMed Scopus (265) Google Scholar). Like virtually all tools, current AD Tg mice are limited in their applicability. However, these models are continually evolving, which should lead to better translation of mouse-discovered therapies into the clinic. Download .pdf (.1 MB) Help with pdf files" @default.
• W1992953921 created "2016-06-24" @default.
• W1992953921 creator A5026487650 @default.
• W1992953921 creator A5050160804 @default.
• W1992953921 creator A5058547941 @default.
• W1992953921 creator A5066725306 @default.
• W1992953921 date "2009-03-01" @default.
• W1992953921 modified "2023-09-30" @default.
• W1992953921 title "Relevance of Transgenic Mouse Models to Human Alzheimer Disease" @default.
• W1992953921 cites W1547058570 @default.
• W1992953921 cites W1586465707 @default.
• W1992953921 cites W1602771322 @default.
• W1992953921 cites W180372312 @default.
• W1992953921 cites W1964049915 @default.
• W1992953921 cites W1967464880 @default.
• W1992953921 cites W1968937229 @default.
• W1992953921 cites W1969311340 @default.
• W1992953921 cites W1971200109 @default.
• W1992953921 cites W1972812487 @default.
• W1992953921 cites W1973276273 @default.
• W1992953921 cites W1976445933 @default.
• W1992953921 cites W1977002082 @default.
• W1992953921 cites W1980750700 @default.
• W1992953921 cites W1981458288 @default.
• W1992953921 cites W1983594867 @default.
• W1992953921 cites W1983829653 @default.
• W1992953921 cites W1984320700 @default.
• W1992953921 cites W1985086842 @default.
• W1992953921 cites W1986413832 @default.
• W1992953921 cites W1990309548 @default.
• W1992953921 cites W1990752558 @default.
• W1992953921 cites W1993909442 @default.
• W1992953921 cites W1995426930 @default.
• W1992953921 cites W1998440070 @default.
• W1992953921 cites W1998832782 @default.
• W1992953921 cites W2002049242 @default.
• W1992953921 cites W2005627616 @default.
• W1992953921 cites W2013706950 @default.
• W1992953921 cites W2019593939 @default.
• W1992953921 cites W2020054158 @default.
• W1992953921 cites W2020824841 @default.
• W1992953921 cites W2031418848 @default.
• W1992953921 cites W2041863676 @default.
• W1992953921 cites W2042835731 @default.
• W1992953921 cites W2045233439 @default.
• W1992953921 cites W2058561815 @default.
• W1992953921 cites W2073420453 @default.
• W1992953921 cites W2075481535 @default.
• W1992953921 cites W2075725519 @default.
• W1992953921 cites W2083358395 @default.
• W1992953921 cites W2088151512 @default.
• W1992953921 cites W2089135389 @default.
• W1992953921 cites W2090023755 @default.
• W1992953921 cites W2103440561 @default.
• W1992953921 cites W2107015337 @default.
• W1992953921 cites W2109727228 @default.
• W1992953921 cites W2110888808 @default.
• W1992953921 cites W2116784956 @default.
• W1992953921 cites W2121448546 @default.
• W1992953921 cites W2137760199 @default.
• W1992953921 cites W2144003253 @default.
• W1992953921 cites W2148371215 @default.
• W1992953921 cites W2156326104 @default.
• W1992953921 cites W2168334242 @default.
• W1992953921 cites W2272671729 @default.
• W1992953921 doi "https://doi.org/10.1074/jbc.r800030200" @default.
• W1992953921 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18948253" @default.
• W1992953921 hasPublicationYear "2009" @default.
• W1992953921 type Work @default.
• W1992953921 sameAs 1992953921 @default.
• W1992953921 citedByCount "134" @default.
• W1992953921 countsByYear W19929539212012 @default.
• W1992953921 countsByYear W19929539212013 @default.
• W1992953921 countsByYear W19929539212014 @default.
• W1992953921 countsByYear W19929539212015 @default.
• W1992953921 countsByYear W19929539212016 @default.
• W1992953921 countsByYear W19929539212017 @default.
• W1992953921 countsByYear W19929539212018 @default.
• W1992953921 countsByYear W19929539212019 @default.
• W1992953921 countsByYear W19929539212020 @default.
• W1992953921 countsByYear W19929539212021 @default.
• W1992953921 countsByYear W19929539212022 @default.
• W1992953921 countsByYear W19929539212023 @default.
• W1992953921 crossrefType "journal-article" @default.
• W1992953921 hasAuthorship W1992953921A5026487650 @default.
• W1992953921 hasAuthorship W1992953921A5050160804 @default.
• W1992953921 hasAuthorship W1992953921A5058547941 @default.
• W1992953921 hasAuthorship W1992953921A5066725306 @default.
• W1992953921 hasBestOaLocation W19929539211 @default.
• W1992953921 hasConcept C102230213 @default.
• W1992953921 hasConcept C104317684 @default.
• W1992953921 hasConcept C141035611 @default.
• W1992953921 hasConcept C142724271 @default.
• W1992953921 hasConcept C158154518 @default.
• W1992953921 hasConcept C169760540 @default.
• W1992953921 hasConcept C17744445 @default.
• W1992953921 hasConcept C199539241 @default.
• W1992953921 hasConcept C2779134260 @default.

• next